anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Whether the benefits of the robotic platform in bariatric surgery translate into superior surgical outcomes remains unclear. The aim of this retrospective study was to establish the 'best possible' outcomes for robotic bariatric surgery and compare them with the established laparoscopic benchmarks.
METHODS: Benchmark cut-offs were established for consecutive primary robotic bariatric surgery patients of 17 centres across four continents (13 expert centres and 4 learning phase centres) using the 75th percentile of the median outcome values until 90 days after surgery. The benchmark patients had no previous laparotomy, diabetes, sleep apnoea, cardiopathy, renal insufficiency, inflammatory bowel disease, immunosuppression, history of thromboembolic events, BMI greater than 50 kg/m2, or age greater than 65 years.
RESULTS: A total of 9097 patients were included, who were mainly female (75.5%) and who had a mean(s.d.) age of 44.7(11.5) years and a mean(s.d.) baseline BMI of 44.6(7.7) kg/m2. In expert centres, 13.74% of the 3020 patients who underwent primary robotic Roux-en-Y gastric bypass and 5.9% of the 4078 patients who underwent primary robotic sleeve gastrectomy presented with greater than or equal to one complication within 90 postoperative days. No patient died and 1.1% of patients had adverse events related to the robotic platform. When compared with laparoscopic benchmarks, robotic Roux-en-Y gastric bypass had lower benchmark cut-offs for hospital stay, postoperative bleeding, and marginal ulceration, but the duration of the operation was 42 min longer. For most surgical outcomes, robotic sleeve gastrectomy outperformed laparoscopic sleeve gastrectomy with a comparable duration of the operation. In robotic learning phase centres, outcomes were within the established benchmarks only for low-risk robotic Roux-en-Y gastric bypass.
CONCLUSION: The newly established benchmarks suggest that robotic bariatric surgery may enhance surgical safety compared with laparoscopic bariatric surgery; however, the duration of the operation for robotic Roux-en-Y gastric bypass is longer.
Patients with diaphyseal humerus fracture or subcapital humerus fracture treated surgically or conservatively, at 6 weeks post stabilization. (Surgical and conservative treatment will be considered as the same population from the functional point of view as functional outcome is similar) (Handoll et al. 2003).
In a process for manufacturing an impression taking material, particularly for taking dental impressions, by reacting a water-soluble alginate or pectate with a water soluble polyvalent metallic salt, the reaction is controlled by using the latter salt in the form of particles coated with a film forming substance which is insoluble in water but soluble in an organic solvent. The metallic salt preferably has a water solubility greater than 2 grams per litre at 20 DEG C., and may comprise potassium alum or calcium lactate or gluconate, and the film forming substance may comprise chlorinated or cyclized rubber or polyvinyl chloride. The gel forming reaction may be further controlled by the addition of sodium or potassium carbonate or pyrophosphate.  In the mixture may also be incorporated fillers such as heavy spar, talc, diatomaceous earth, precipitated calcium carbonate, alumina, magnesium carbonate, and calcined magnesia.  In one example 25 parts by weight of pulverized potassium alum dodecahydrate are suspended in 500 parts of a 10 per cent solution of cyclized rubber in methylene chloride and atomized and dried, 2.5 parts of the coated alum particles, 5 parts of sodium alginate, and 20 parts of precipitated calcium carbonate are stirred with 50 parts of water to yield a creamy mass which sets as an elastic gel.  In further examples coated calcium lactate particles are prepared by atomizing a suspension of the pulverized salt in a solution of cyclized rubber in petroleum ether or methylene chloride, or of chlorinated rubber in methylene chloride.  The coated calcium lactate particles may be mixed with sodium alginate, heavy spar, and talc, and a gel may be formed by adding a solution of the sodium salt of ethylene amine tetra-acetic acid.
Method for predicting sensitivity of a patient suffering from cancer to DNA methylation inhibitor therapy uses in vitro in cancer cells taken from the patient. Cells are compared with parent type cells for expression of bromodomain containing genes, of other listed genes, and/or of bromodomain containing proteins. Mutations involving the amino acid sequence of bromodomain containing genes and/or mutations involving non-synonymous change in amino acid sequence of other genes may be examined. The half maximal inhibitory concentration (IC 50 ) of inhibitors of DNA methyltransferase, histone acetyltransferase, histone methyltransferase, histone deacetylases, and/or histone demethylases are determined. Increase in (IC 50 ) signifies cross-resistance. The half maximal inhibitory concentration (IC 50 ) of a selective BET bromodomain inhibitor is also determined, wherein decrease in the (IC 50 ) signifies sensitivity. A combination therapy for cancers using bromodomain inhibitors in combination with DNA methylation inhibitors is also provided.
INTRODUCTION: Adverse events in health care affect 8% to 12% of patients admitted to hospitals in the European Union (EU), with surgical adverse events being the most common types reported.
AIM: SAFEST project aims to enhance perioperative care quality and patient safety by establishing and implementing widely supported evidence-based perioperative patient safety practices to reduce surgical adverse events.
METHODS: We will conduct a mixed-methods hybrid type III implementation study supporting the development and adoption of evidence-based practices through a Quality Improvement Learning Collaborative (QILC) in co-creation with stakeholders. The project will be conducted in 10 hospitals and related healthcare facilities of 5 European countries. We will assess the level of adherence to the standardised practices, as well as surgical complications incidence, patient-reported outcomes, contextual factors influencing the implementation of the patient safety practices, and sustainability. The project will consist of six components: 1) Development of patient safety standardised practices in perioperative care; 2) Guided self-evaluation of the standardised practices; 3) Identification of priorities and actions plans; 4) Implementation of a QILC strategy; 5) Evaluation of the strategy effectiveness; 6) Patient empowerment for patient safety. Sustainability of the project will be ensured by systematic assessment of sustainability factors and business plans. Towards the end of the project, a call for participation will be launched to allow other hospitals to conduct the self-evaluation of the standardized practices.
DISCUSSION: The SAFEST project will promote patient safety standardized practices in the continuum of care for adult patients undergoing surgery. This project will result in a broad implementation of evidence-based practices for perioperative care, spanning from the care provided before hospital admission to post-operative recovery at home or outpatient facilities. Different implementation challenges will be faced in the application of the evidence-based practices, which will be mitigated by developing context-specific implementation strategies. Results will be disseminated in peer-reviewed publications and will be available in an online platform.
The investigators current treatment for preterm labor has not been shown to be effective in prolonging pregnancy sufficiently to improve neonatal outcomes and other treatment strategies are needed. Multiple examples demonstrate that multi-agent treatments are routine clinical practice in other fields of medicine including chemotherapeutics for cancer, multi-therapeutics for myocardial infarction and broad spectrum antibiotics for pneumonia. At this time, it is unclear if a combination of tocolytic medications for preterm labor is more advantageous for women. If pregnancy is prolonged with combined tocolytic therapy, this could directly influence the treatment of preterm labor and potentially improve neonatal outcomes. There currently are no trials of combination regimens using widely used tocolytic agents, such as nifedipine and indomethacin. Thus, we propose a comparative effective trial of nifedipine plus indomethacin vs. nifedipine alone for the treatment of preterm labor
The SMART Guide surgical template is applied only in the initial phase of the operation. After having prepared soft tissue access, the template is placed, and only one drilling is performed through its sleeve, with the so-called pilot drill. The resulting borehole serves as directional guidance for the drills applied later in the process. Further drilling and implant insertion are both performed freehand. At the end of the operation, the operation site is checked, hemostasis is provided, and the operator records the operation in the source documentation. 2±1 days later, a postoperative CT scan is taken. A follow-up visit is due 14±2 weeks later, after the osseointegration period.
The birth of a child can trigger relationship distress and dissolution. Family Expectations (FE) targets the transition to parenthood as a critical time to help couples focus on family success. Regardless of whether couples are married or unmarried, the goal of FE is to strengthen relationships and advance the well-being of economically disadvantaged couples who are expecting a baby or who are new parents, and to improve the lives of their children. The FE program, including the Becoming Parents (BP) curriculum and supplemental services, is designed to address specific risk factors that affect individual family members and the relationships among them, and to build protective factors that help families avoid, minimize, or manage risks (e.g., individual maladaptation \[mother, father, child\], couple relationship difficulties, parenting difficulties, and economic insufficiency).

A total of 1,355 couples will be randomly assigned to either Family Expectations (n = 813; 60%) or an untreated control group (n = 542; 40%). Once assigned, participants in the study will complete baseline questions by survey. Those assigned to the FE track will be scheduled for services with the FE intervention team and the control group will not receive the FE intervention. Members of the intervention and control groups will be surveyed both before they are randomly assigned and 12 months later. The study will examine if the Family Expectations program is associated with improved outcomes on relationship quality, stability, parenting quality, father involvement, child wellbeing, and hopefulness about employment.
Polymicrobial sepsis is associated with a poor prognosis due to severe type-1 innate inflammation triggered by immune cells, such as dendritic cells and macrophages. This immune response frequently leads to damage in the heart. Although interleukin (IL)-13 is thought to play a protective role in organ inflammation, its function in polymicrobial sepsis remains unclear. We aimed to investigate the role of IL-13 in modulating myocardial injury during cecal ligation and puncture (CLP)-induced sepsis using a murine model. Cardiac troponin I (cTnI), a biomarker for myocardial damage, was measured in both IL-13-deficient (KO) and wild type (WT) mice subjected to CLP. Contrary to the conventional view of IL-13 as a protective cytokine, IL-13-competent mice exhibited significantly higher serum cTnI levels than IL-13-deficient mice, indicating exacerbated myocardial injury. Elevated cardiac tumor necrosis factor-alpha (TNF-α) levels and IL-1β in WT CLP mice corroborated this finding, suggesting IL-13's role in enhancing the inflammatory response. In vitro assays with bone marrow-derived dendritic cells (BMDCs) stimulated with lipopolysaccharide and Group A Streptococcus revealed a dose-dependent suppression of TNF-α and IL-6 production by recombinant IL-13. These findings indicate a complex role of IL-13 in sepsis, modulating inflammation but potentially increasing myocardial stress.
FIRES and NORSE are clinical presentations of disease processes that, to date, remain unexplained without an established etiology in many cases. Neuroinflammation is thought to have paramount importance in the genesis of these conditions. We hereby report the clinical, EEG, brain MRI, and genetic findings of a nuclear family with recurrent febrile-related encephalopathy with refractory de novo Status Epilepticus. Whole-exome sequencing (WES) revealed a homozygous p.C105W pathogenic variant of FADD gene (FAS-associated protein with death domain, FADD), known to cause ultrarare forms of autosomal recessive immunodeficiency that could be associated with variable degrees of lymphoproliferation, cerebral atrophy, and cardiac abnormalities. The FADD-related conditions disrupt FAS-mediated apoptosis and can cause a clinical picture with the characteristics of FIRES. This observation is important because, on one hand, it increases the number of reported patients with FADD deficiency, showing that this disorder may present variable expressivity, and on the other hand, it demonstrates a genetic cause of FIRES involving a cell-mediated inflammation regulatory pathway. This finding supports early treatment with immunomodulatory therapy and could represent a new avenue of research in the field of new onset refractory status epilepticus and related conditions.
OBJECTIVE: To analyze and evaluate the efficacy of different blue light therapy methods and provide evidence-based recommendations for their selection in clinical practice.
METHODS: Clinical randomized controlled trials (RCTs) evaluating the efficacy of various blue light therapy methods for neonatal jaundice were retrieved from both domestic and international databases. The search period covered the inception of each database until November 2023. After screening, the quality of the included studies was assessed using the Cochrane Risk of Bias tool. Literature management was conducted with NoteExpress 3.2, while data collection and extraction were performed using Excel 2003. Statistical analysis was carried out using RevMan 5.4.1. Heterogeneity was assessed using the Q test (p value), and the OR value of the combined effect was calculated using either a fixed-effects or random effects model, depending on the presence of heterogeneity. A forest plot was generated to visualize the results. Sensitivity analysis was performed by excluding the largest-weighted study, and the potential for bias in outcome indicators was assessed using a funnel plot.
RESULTS: A total of 652 articles were retrieved, with 16 clinical RCTs meeting the inclusion criteria. The meta-analysis results indicated that, compared to continuous blue light therapy in the control group, intermittent blue light therapy achieved a higher total effective rate (OR = 1.82, 95%CI (1.25-2.64), p = .002), significantly lower serum bilirubin levels post-treatment (OR = -14.59, 95%CI (-26.11 to -3.08), p = .01), and a shorter time to jaundice resolution (OR = -2.35, 95%CI (-3.83 to -0.87), p = .002). Additionally, the incidence of adverse reactions was lower in the intermittent therapy group compared to the control group (OR = 0.27, 95%CI (0.19-0.36), p < .00001). Sensitivity analysis confirmed that the combined effect size was stable and reliable (OR (95%CI) = -16.23 (-28.67 to -3.79), p = .01). The funnel plot suggested potential publication bias.
CONCLUSIONS: Intermittent blue light therapy is effective and demonstrates significant clinical benefits, making it a valuable treatment option for neonatal jaundice in clinical practice.
In forensic entomology, the time-related growth and development of carrion insects allows for the estimation of the minimum postmortem interval (PMImin). Piophila megastigmata (Diptera: Piophilidae) is of great significance in estimating PMImin in the late stage of corpse decay. In this paper, the development of P. megastigmata was investigated under the seven constant temperatures of 16-34 °C. The total development time at each temperature was 970.38, 824.50, 593.13, 498.25, 392.00, 385.63 and 405.87 h, respectively. The isomorphen diagram shows the trend of development during different developmental stages at different temperatures. By using a revised linear regression model, the estimated lower lethal developmental thresholds (TL) and thermal summation constant (K) were found to be 10.57 °C and 6936.78 degree hours, respectively. According to a nonlinear model, the TL, upper lethal developmental thresholds (TH), and intrinsic optimum temperature (TΦ) were determined to be 7.53, 34.68, and20.43 °C, respectively. Also, logistic function and an isomegalen diagram were constructed according to the continuous changes in larval body length, and illustrates the time required to develop to a certain length at different temperatures. The obtained results offer crucial fundamental developmental information regarding P. megastigmata, which can be applied in PMImin estimation.
Heart failure is an emerging epidemic in especially the elderly, with high mortality rates, substantial loss in quality of life, and high healthcare costs, mainly due to hospitalizations. The majority of (usually elderly) patients with heart failure are diagnosed and managed in primary care. However underdiagnosis and undertreatment of patients with heart failure in primary care are common. Implementation of a standardized diagnostic protocol together with educating general practitioners in a pragmatic treatment strategy in which the focus lays on uptitration of heartfailure medication, would fill the gap of underdiagnosis and undertreatment that nowadays exists in primary care.

All participants will undergo a standardized diagnostic work-up to establish or rule out heart failure. In those participants with an abnormal ECG and/or elevated natriuretic peptide level additional echocardiography will be performed at the outpatient clinic of the Diakonessenhuis in Zeist. The definite diagnosis of heart failure ('systolic' or 'diastolic') will be established by an expert panel consisting of two cardiologists and a general practitioner. The panel will apply the criteria of the updated heart failure guidelines (2008) of the European Society of Cardiology (ESC). Patients with heart failure will subsequently be treated by their own general practitioner. The participating general practitioners will be randomly divided into either care as usual (control group) or special uptitration (intervention group). Both groups will be using medication as recommended in the Dutch heart failure standard. However, general practitioners in the intervention group will be especially trained in the practical appliance of this guideline: the initiation of diuretics and ACE-inhibitors and structured uptitration of ACE-inhibitors and beta-blockers. In the training, practical examples will be used concerning barriers the general practitioners themselves encountered when using this medication. In the intervention group, patients with 'systolic' heart failure will receive the recommended maximal dose or the highest tolerated dose. Patients with 'diastolic' heart failure will receive optimal blood pressure and heart rate control with the preferred cardiovascular drugs. At baseline and six months after heart failure is established or ruled out, participants are asked to perform the six-minute walk test and fill out quality of life questionnaires. During those six months, only participants with heart failure will additionally fill out one of these questionnaires every three weeks. Also after six months, electronical files of the general practitioners will be scrutinized to assess the (dosage of) prescribed medication and visits to general practice and cardiology department.
After providing a written inform consent, potential patients will undergo a 2-weeks screening period to determine if they meet eligibility criteria. Baseline information (i.e., derived from semi-structured intake interviews and baseline clinical measures) from patients who meet eligibility criteria and consent to participate in the study, will be use to feed a machine learning algorithm, developed in a previous study, to perform individual predictions and determine which interventions (i.e., cognitive, behavioral, interpersonal, or patient-centered) will be recommended for the individual patient. This recommendation (i.e., about the most personally well-suited intervention for a given patient) will be provided to therapists before the beginning of treatment. Patients will be treated with 15 sessions of psychotherapy. The investigators will examine the extent to which therapists adhered to the recommended interventions as the primary outcome. The investigators will also examine patient symptomatic/functional improvement as a secondary outcome.
A nutritional supplement for use to ameliorate the effect of a pneumonia in a human, wherein the supplement comprises a mixture of bioflavonoids which contains at least 45% wt/wt (of the total bioflavonoids) of naringin and at least 15% wt/wt of neohesperidin, wherein the supplement is in a form suitable for oral administration or administration to the lung by insufflation or inhalation. The pneumonia is preferably caused by a coronavirus, particularly SARS-CoV-2. The mixture of bioflavonoids preferably comprises bioflavonoids obtained from oranges, for example, the pith of bitter oranges, such as immature bitter oranges. The nutritional supplement may further comprise vitamin D, such as vitamin D3 or 25-hydroxyvitamin D3, cyclodextrin, or glycosaminoglycan, preferably hyaluronic acid. A nutritional supplement for use to ameliorate a hyperimmune condition, wherein the supplement comprises a mixture of bioflavonoids which contain at least 45% by weight (of the total bioflavonoids) of naringin and at least 15% wt/wt of neohesperidine is also provided. Preferably the hyperinflammatory condition occurs in the lungs and is as a result of a coronavirus infection, particularly SARS-CoV-2. The hyperinflammatory condition may occur in a human suffering from sepsis or toxic shock syndrome. A nutritional supplement as herein defined for administration by inhalation is also provided.
A prodn. method for native, stable immunoglobulin (IgG) for intravenous use is claimed in which (i) below 8 deg.C a total globulin ppte. of less than 1% polymers is obtd. by known methods, (ii) (i) is extracted at a slightly acidic pH with a slightly ionic aq. extracting agent to form a clarified extract for a fine purificn., (iii) the IgG-soln. obtd. is used to produce a physiologically applicable prepn., wherein (i) if necessary is adjusted to a solvent residue of water with 35-40 vol.-% methanol, pH 6.5-7.0, extracted at 2-8deg.C with H2O and 38-42 vol-%. methanol, and the extraction mixture is kept at pH 4.7-5.3 at a methanol concn. of 38-42 vol-%. in the methanol/H2O mix whilst clarifying the extract for the fine purificn. USE/ADVANTAGE - An IgG with unchanged antibody activity and lacking anti-complement activity is produced as a prophylactic agent and for treatment of infectious diseases and antibody-deficiencies in animals and humans. The prodn. method described isolates separate IgGs from total globulin with a cheap extraction agent under defined, easily adjustable conditions in a single extraction step directly prior to the fine purificn. This eliminates chromatography or series of pptns. required in prior art methods
Participants will receive 2 doses of Cardiosyn daily by mouth (2 sachets) for a total of 16.2 grams. Each does (sachet) is 8.1 grams.
The control group will continue the routine pediatric physiotherapy program 3 days a week. This program, which includes exercises appropriate to the child's motor function level, includes stair climbing, walking exercises, balance, strengthening and flexibility exercises.